设为首页         

资讯内容 Content

[ESC2009]单片复方制剂(SPC)倍博特在高血压治疗中的应用和优势--Weir教授专访
国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

 编辑:国际循环网 时间:2009/9/3 18:26:00    加入收藏
 关键字:单片复方制剂 高血压治疗 倍博特 阿利吉仑 


International Circulation:  Can you discuss the safety and target organ protection of valsartan/ amlodipine SPC (Exforge®) in antihypertensive therapy?

《国际循环》:您能否评价一下缬沙坦氨氯地平单片(Exforge®)在抗血压治疗中的安全性和靶器官保护作用?

Professor Weir:  Well both of the chemicals valsartan and amlodipine are old friends in the sense that they have been studied extensively in numerous large scale clinical trials.  So we have the advantage and the confidence of knowing how to dose them both alone and together as part of an effective blood pressure lowering strategy.  Again valsartan has been studied extensively in people with heart failure, post myocardial infarction, and of course in high blood pressure.  And certainly amlodipine has been studied extensively in many many cardiovascular outcome trials and between the two of them we really have a wealth of experience in their use.

Weir教授:缬沙坦和氨氯地平这两种药物均已经在众多大型临床试验中被广泛研究过,从这个意义上来说,它们都是我们的老朋友了。因此作为有效降压策略的一部分,无论单用还是联合,我们都有优势和信心知道如何应用。再则,缬沙坦已经在心力衰竭、心肌梗死后和高血压人群中被广泛研究;同时,氨氯地平也已经在很多心血管终点试验中被广泛研究。对这两种药物,我们确实有非常丰富的应用经验。



上一页  [1]  [2]  [3]  [4]  [5]  [6]  下一页

   评论发言          
 
京ICP备15014970号-5   国际循环 版权所有  2008-2022 icirculation.com  All Rights Reserved